Cantor Fitzgerald raised the price target for the Fulcrum Therapeutics Inc (NASDAQ:FULC) stock to “an Overweight”. The rating was released on May 20, 2024, according to finviz. The research report from Goldman has initiated the stock to Neutral, with a price target set at $5. The stock was upgraded by H.C. Wainwright, who disclosed in a research note on August 23, 2023, from Neutral to Buy and set the price objective to $14. In their research brief published August 22, 2023, Stifel analysts upgraded the Fulcrum Therapeutics Inc stock from Hold to Buy with a price target of $11.
The latest trade, Performances and Moving Averages give us the following Picture
The firm’s stock price fluctuated 8.41% within the last five trades and 47.07% within the last 30 trades, which was a significant change from the beginning of this year. Despite the fact that the share price increased 28.18% in the last 6 months and 30.15% was added to its value over the previous 3 months. FULC stock is trading at a margin of 19.07%, 23.37% and 29.67% apart from the 20-Day, 50-Day and 200-Day Simple Moving Average prices.
Sponsored
As of the close of trading, FULC deals in the Healthcare domain. The stock is trading -32.26 percent below its 52-week high and 195.54 percent above its 52-week low. For example, looking both at the price and the high and low measurements of 52 weeks will give you a clearer picture of the direction the price is heading. The firm’s Weighted Alpha is 81.13. A positive weighted alpha indicates the firm has done well over the course of the year, whereas one below 0 indicates that the firm has done poorly.
What Does Fulcrum Therapeutics Inc’s Profitability and Valuation Ratios Tell Us About the Stock?
With regard to the profitability of the company, the operating margin is currently at -4484.38 percent and the profit margin is -3961.20 percent, and the company has reported a gross margin of 16.85 percent. The profit margin, also known as the revenue ratio or gross profit ratio, is an efficiency figure used to estimate the business’s profitability by comparing net income and sales. The higher the number, the more profits are generated for the company and vice versa.
The stock’s market cap achieved a total value of $576.75 million as of the last trading session. Market capitalization is the total value of all outstanding shares of a corporation and it is used to measure a company’s market value. Forward price-to-earnings is calculated using predicted earnings for the next financial year’s P/E determination. The stock has achieved an effective Price-to-Sales Ratio of 229.78 that mirrors the cost to be found for sales by the market. The firm managed a Price-to-Book ratio of 2.70, which equates the market value of a stock with its book value.
Is Insider Trading a Real Thing?
Almost all investors and traders prefer to invest in shares controlled by the management of a corporation as a management company will be more likely to run the business itself and to never conduct things against the management’s desires and will always try to do what is best for their shareholders. Currently, 7.27 percent of Fulcrum Therapeutics Inc shares are owned by insiders, and 92.70 percent are held by financial institutions. Tourangeau Greg, the Principal Accounting Officer at Fulcrum Therapeutics Inc (FULC) has sold 236 shares of firm on May 07 ’24 at a price of $7.76 against the total amount of $1831.0. In another inside trade, Tourangeau Greg, Vice President, Finance of Fulcrum Therapeutics Inc (NASDAQ:FULC) sold 4,884 shares of the firm on Mar 08 ’24 for a total worth of $57219.0 at a price of $11.72. An inside trade which took place on Mar 04 ’24, of Fulcrum Therapeutics Inc Sapir Alex bought 43,360 shares of firm against total price of $0.49 million at the cost of $11.35 per share.
